Perspective Therapeutics, Inc. (CATX) is working on developing one of its lead drugs known as VTM-a-NET for the treatment of patients with unresectable or metastatic somatostatin receptor type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results